Instituto de Medicina Molecular (iMM) - Coordinating Institution

 

iMM Lisboa

Av. Professor Egas Moniz

1649-028 Lisboa

Portugal

undefinedWebsite

 

 

Project Coordinator

Prof. João Mascarenhas Forjaz Lacerda, MD PhD

Phone: +351 217 999 566

Fax: +351 217 985 169

undefinedE-Mail

 

Project team

Maria Godinho Duarte Soares, PhD

Researcher iMM

Phone: +351 217 999 566

undefinedE-mail

Rita I. Azevedo, PhD

Researcher iMM

Phone: +351 217 999 566

undefinedE-mail

Paulo N. G. Pereira, PhD

Clinical Study Coordinator

Phone: +351 217 999 566

undefinedE-mail

Nadia Camacho

Technical Assistant,

Bone Marrow Transplantation Unit, Hospital de Santa Maria, Lisboa
Phone: +351 217 805 000 (ext 94135)
Fax: +351 217 805 314

undefinedE-mail

Clara Juncal, MD

Attending Physician,

Cell Therapy Facility,

Hospital de Santa Maria, Lisboa
Phone: +351 217 805 000 (ext 51438)

undefinedE-mail

Ana Alho, MD PhD Student

Hematology Fellow, Hospital de Santa Maria, Lisboa

undefinedE-mail

Eduardo Espada, MD PhD Student

Hematology Fellow, Hospital de Santa Maria, Lisboa

undefinedE-mail

J. Alves Carmo, MD

Attending Physician,

Head of the Hematology and Bone Marrow Transplantation Service, Hospital de Santa Maria, Lisboa
Phone: +351 217 805 295

undefinedE-mail

Carlos Martins, MD

Attending Physician,

Hematology and Bone Marrow Transplantion Service, Hospital de Santa Maria, Lisboa
Phone: + 351 217 805 295

undefinedE-mail

António Campos, MD

Attending Physician, Head Bone Marrow Transplantion Service, Instituto Português de Oncologia, Porto

undefinedE-mail

Carlos Pinho Vaz, MD

Attending Physician, Bone Marrow Transplantion Service, Instituto Português de Oncologia, Porto

undefinedE-mail

Isabelina Ferreira, MD

Attending Physician, Bone Marrow Transplantion Service, Instituto Português de Oncologia, Lisboa

undefinedE-mail

Anabela Rodrigues, MD

Attending Physician, Cell Therapy Facility, Hospital de Santa Maria, Lisboa
Phone: +351 217 805 000 (ext 51438)

undefinedE-mail

About the iMM

Instituto de Medicina Molecular (iMM Lisboa) is a reference biomedical research center in Portugal, having acquired the special status of Associate laboratory of the Portuguese Ministry of Science and Technology. iMM’s mission is to promote basic, translational and clinical biomedical research with the aim to understand the mechanisms of disease and develop novel therapeutic approaches.

 

iMM Lisboa is a partner of Hospital de Santa Maria, the largest hospital in Portugal, and Faculdade de Medicina da Universidade de Lisboa, in Lisbon’s Academic Medical Center. The Hematology and Bone Marrow Transplant Service of Hospital de Santa Maria is one of the three centers in Portugal performing allogeneic hematopoietic stem cell transplantation (HSCT). It was a pioneer in the country in several transplant techniques, such as cryopreservation, the use of peripheral blood progenitor cells as the source of graft and haploidentical related HSCT. It is also considered a reference center for alternative donor HSCT. For the current project, collaborations were established with the other two centers in Portugal performing allogeneic HSCT, Instituto Português de Oncologia in Lisboa and Porto.

 

João Forjaz de Lacerda is an Attending Physician in the Hematology and Bone Marrow Transplantation Service of Hospital de Santa Maria, Associate Professor of Medicine and Head of Hematology at the University of Lisbon, and Group Leader of a translational research unit focusing on Hematology and Transplantation Immunology at iMM Lisboa. He performed his training in Lisbon and at Memorial Sloan-Kettering Cancer Center, in New York, USA.

 

João Lacerda’s Lab at iMM Lisboa is located within the campus of Hospital de Santa Maria, making it the ideal setting in which bench to bedside projects can thrive. The main research area of his group is the study of immune reconstitution after HSCT in humans and the development of strategies that modulate immune responses and tolerance post-transplant. Donor immunity emerging post-transplant plays a pivotal role in the protection against pathogens, as well as in the graft-versus-leukemia effect. On the other hand, donor-derived immune cells can cause graft-versus-host disease (GVHD) by attacking normal tissues of the patient. Opportunistic infections, such as Aspergillus, CMV and EBV, also constitute major causes of morbidity and non­relapse mortality following HSCT. João Lacerda’s Lab aims to identify immunological risk factors and the mechanisms by which these complications emerge post-transplant. They are particularly interested in developing strategies that may be translated into the clinical setting, such as the use of pathogen-specific T cells, donor regulatory T cells for GVHD and disease-specific T cells, with the aim of improving patient survival.

 

João Lacerda’s group has been financed by the national funding agency in Portugal (FCT - Fundação para a Ciência e a Tecnologia) through a collaborative research grant of the Harvard Medical School-Portugal Program, together with Jerome Ritz’s group at the Dana-Farber Cancer Institute in Boston, USA.

The TREGeneration partners

Search
Home
Menu
Top

Newsletter Subscription

Please fill in the information of your subscription.

 

You have already subscribed to Newsletter Recipients and wish to update or terminate your subscription? Click here!

News Section

TREGeneration team welcomes three external speakers Read more

Social Media

LinkedIn TREGeneration